Why hip cartilage cannot repair itself

Hip articular cartilage has no meaningful ability to repair itself — and the reason lies in its basic anatomy. The smooth cartilage lining the femoral head and the cup of the acetabulum is avascular: it contains no blood vessels. Without a blood supply, the body cannot mount the inflammatory repair cascade that heals most other tissues after injury. There are also no nerves running through it, which is why cartilage damage can progress silently for years before pain becomes significant.

The tissue itself is a tightly organised matrix of proteoglycans, glycosaminoglycans, and collagen fibres — a structure that gives cartilage its ability to absorb and distribute the considerable loads passing through the hip joint with every step. When that matrix is disrupted, whether by femoroacetabular impingement (FAI), a sports injury, repetitive stress, or age-related wear, the resident chondrocyte cells simply cannot migrate to the damage zone and rebuild what has been lost. They have neither the stimulus nor the means.

It is also worth being clear about what the body can sometimes produce: fibrocartilage — a scar-like tissue that fills gaps but lacks the organised collagen architecture and mechanical resilience of native hyaline cartilage. This distinction matters throughout the discussion of treatment techniques, because some procedures produce fibrocartilage and others aim to restore something closer to true hyaline cartilage. The gap between the two is not merely academic; it affects how long a repair holds up under load.

No oral supplement, dietary change, or over-the-counter product has regulatory approval to rebuild hip articular cartilage. This is not a counsel of despair — it is precisely why clinicians have developed the range of surgical and regenerative techniques described below, each specifically designed to substitute for, or stimulate, tissue the hip joint cannot recreate on its own.

Who is a realistic candidate for cartilage restoration in the hip

Cartilage restoration surgery is not appropriate for every hip patient — and being honest about that boundary is as important as describing what the techniques can achieve.

The clearest eligibility marker is the nature of the damage itself. Restoration techniques are designed for focal, contained defects — typically Outerbridge or ICRS grade II to IV — where cartilage has thinned or broken down in a localised area while the surrounding joint remains relatively intact. Defect size matters too: different techniques suit different sizes, from smaller lesions addressable by scaffold injection or microfracture through to larger posttraumatic defects requiring cell-based repair or osteochondral grafting. What these approaches cannot do is restore a hip that has lost cartilage diffusely across the joint surface. For advanced bone-on-bone osteoarthritis, regenerative surgery is not the right pathway; hip replacement remains the appropriate and well-evidenced option at that stage.

Age is a strong practical filter. A German epidemiological study of 116,179 hip cartilage repair procedures performed between 2006 and 2022 found that patients undergoing these techniques averaged just 27.73 years of age. Evidence is most robust in patients under 50, where the remaining joint architecture gives a repair the best chance of long-term function.

Underlying hip mechanics matter equally. Femoroacetabular impingement or a torn labrum left unaddressed will continue to stress a repaired cartilage surface and compromise results — these structural problems typically need to be corrected at the same time as any restoration work. A particular pattern worth identifying early is chondrolabral delamination, where cartilage begins to separate at the junction with the labrum; research in porcine models shows that early surgical refixation significantly improves tissue regeneration compared with delayed treatment.

A consultant assessment — including MRI and a review of hip mechanics — is needed to determine which pathway is appropriate for any individual patient.

Surgical techniques for restoring hip cartilage

Operative options for hip cartilage restoration form a logical spectrum — from the simplest marrow-stimulation procedures through single-stage scaffold techniques to the most resource-intensive two-stage cell-based approaches. Selecting among them depends on defect size, lesion depth, patient age, and the quality of the surrounding joint.

Microfracture — an historical first-line now in decline

For many years, microfracture was the standard starting point for small focal defects under 2 cm². The technique involves drilling fine perforations into the subchondral bone to recruit marrow stem cells, which form a repair layer. The fundamental limitation — introduced briefly in the previous section — is that this repair tissue is fibrocartilage, not true hyaline cartilage. Published evidence now shows that fibrocartilage repair begins to deteriorate at two to three years under load, and the drilling itself can damage the subchondral bone plate in a way that complicates any later, more ambitious repair attempt. Microfracture should not be framed as a modern first-line recommendation.

A 2025 rabbit study added an important nuance: simultaneously preserving the labrum and repairing the hip capsule produced significantly better cartilage healing alongside microfracture — with higher type II collagen and aggrecan expression — than microfracture alone. Joint stability, it appears, is as important as the marrow stimulation itself.

AMIC — scaffold-augmented single stage

Autologous matrix-induced chondrogenesis (AMIC) addresses microfracture's core weakness by adding a scaffold membrane over the drilled defect to retain and organise the recruited cells. This single-stage approach bridges the gap between bare marrow stimulation and fully cell-based implantation, and is better suited to retaining repair quality over time.

OATS and mosaicplasty — transferring intact cartilage

For defects in the 1–2 cm² range — or up to approximately 4 cm² in mosaic configurations — osteochondral autograft transfer (OATS) moves a full-thickness plug of bone and overlying cartilage from a low-load donor site within the joint to the damaged area. The immediate structural advantage is that the transferred tissue is genuine hyaline cartilage. Donor-site morbidity is a meaningful clinical consideration and should be discussed with patients in advance.

ACI and MACI — two-stage cell-based repair

Autologous chondrocyte implantation (ACI) and its matrix variant (MACI) represent the most biologically ambitious current approach. In both, cartilage cells are harvested at an initial arthroscopy, expanded in a laboratory over several weeks, then reimplanted — in MACI, seeded onto a Type I/III collagen membrane — at a second procedure. These techniques are appropriate for larger defects in the 2–10 cm² range and offer the closest current approximation to restoring hyaline-like cartilage architecture in the hip. The two-stage commitment and recovery demands are substantial, and careful patient selection is essential.

Emerging arthroscopic delivery systems — using transcapsular and translabral needle access — are beginning to make single-session orthobiologic and scaffold treatments technically feasible for both the acetabulum and femoral head, potentially broadening the range of patients who can be treated without open surgery.

ChondroFiller injection: an outpatient scaffold pathway for focal hip defects

Unlike the surgical restoration techniques covered above, the ChondroFiller injection pathway reaches the hip joint without an operating theatre or arthroscopic access. It is delivered as an ultrasound-guided outpatient procedure — placing it in a separate clinical category from the cell-based and scaffold-augmented surgical options described in the previous section.

ChondroFiller is an acellular injectable collagen scaffold, CE-marked as a Class III medical device. Under image guidance, it is introduced directly into the focal cartilage defect, where it gels in situ. The scaffold itself contains no cells; instead, the collagen matrix creates the structural environment needed to recruit the patient's own progenitor cells, initiating matrix-induced chondrogenesis. As new tissue forms, the scaffold biodegrades.

The pathway is suited to focal hip cartilage defects up to approximately 3 cm², with device data indicating the approach may extend to around 6 cm² in appropriate cases. Diffuse osteoarthritis and widespread cartilage loss fall outside this indication — surgical restoration or, where the joint is end-stage, hip replacement remain the appropriate options in those presentations.

Hip-specific outcome data show a mean improvement in modified Harris Hip Score of approximately 30 points. MOCART imaging scores in the range of 70–87 suggest meaningful cartilage fill on MRI, and a published complaint rate of approximately 0.06% supports a favourable safety profile for the outpatient route.

A clarification that patients often raise: ChondroFiller injection and Arthrosamid are not interchangeable treatments. Arthrosamid is a non-regenerative polyacrylamide hydrogel that acts as a joint spacer; the ChondroFiller injection is a regenerative scaffold designed to support new tissue formation within a focal defect. The two work by different mechanisms and address different clinical situations.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

What the 2025–2026 research actually shows

The most directly applicable recent finding for hip patients comes from a 2025 prospective case-control study of 112 people undergoing hip arthroscopy for ICRS grade 2–4 cartilage defects. At four years, the group treated with mesenchymal stem cell (MSC) augmentation showed a modified Harris Hip Score rise from 63.5 to 87.2, compared with 66.2 to 83 in the microfracture-alone control group. More telling than the headline scores was what happened at the four-year mark: 20% of the microfracture-only group experienced late deterioration — consistent with the fibrocartilage breakdown pattern noted in the surgical techniques section. The MSC-augmented group maintained their gains, supporting augmentation as a more durable long-term option for the right patient.

The 15-PGDH discovery — genuine science, still preclinical for the hip

The most widely reported cartilage science of 2025–2026 comes from Stanford Medicine. Researchers identified 15-PGDH — an ageing-related enzyme they term a 'gerozyme' — as a significant driver of cartilage loss. Blocking it with a small molecule reversed cartilage deterioration in ageing mice, prevented arthritis after joint injury, and, when human hip and knee tissue samples from replacement surgery were exposed to the treatment, prompted new functional cartilage production. An oral formulation is already in early clinical trials, though for age-related muscle weakness rather than cartilage. For hip cartilage specifically, the work remains preclinical; no clinical application is yet available. The distinction matters: this is a credible mechanistic advance pointing toward true regeneration, not an imminent treatment option.

Gene and genome-editing therapies — including delivery of bone morphogenetic proteins — occupy a similar position: scientifically plausible, active in research, but not yet in clinical practice.

Why outcomes data will improve: MERCH

A persistent weakness in the field has been the absence of a standardised tool for measuring how well cartilage repair actually performs on imaging. The MERCH scoring system, introduced in 2023, addresses this directly — a seven-domain MRI assessment requiring at least 12 months' post-operative follow-up and a 3.0T scanner. As MERCH is adopted prospectively, it will enable more meaningful comparisons between techniques than the heterogeneous outcome measures used in earlier studies.

The evidence gap

Taken together, the 2026 picture is one of careful optimism: regenerative techniques demonstrably work, MSC augmentation extends their durability, and mechanistic science is moving toward true cartilage regeneration. What the field still lacks is a head-to-head randomised controlled trial comparing all major restoration approaches specifically in the hip. Most high-quality data remain short to medium term. For patients weighing their options, that context is as important as the promising individual findings.

When to seek assessment for hip cartilage damage

Symptoms that prompt concern about hip cartilage damage are often subtle at first. Deep groin pain, a mechanical clicking or catching sensation during movement, stiffness after sitting for a period, and activity-related pain that fails to settle with rest are all signals worth investigating — particularly in younger or active adults, where a focal defect caught early still falls within the treatable range.

The underlying principle guiding assessment is that early detection significantly broadens the options available. Most patients progress through a four-stage pathway rather than moving directly to surgery. Stage one is symptom management — activity modification, physiotherapy, and analgesia. Stage two is biologic or injection support: treatments such as platelet-rich plasma or hyaluronic acid to reduce inflammation and support the joint environment. Stage three is cartilage restoration or scaffold repair — procedures such as the ChondroFiller injection, osteochondral autograft, or cell-based ACI, matched to defect size and patient profile. Stage four, when none of the preceding stages can offer realistic benefit, is hip replacement. The staging matters: most patients should progress through it sequentially rather than skipping steps.

Imaging underpins every decision along that pathway. A standard X-ray can miss early cartilage loss entirely; an MRI, ideally at 3.0T, is needed to grade lesion severity and confirm whether restoration remains viable.

Where bone-on-bone hip osteoarthritis is already established, the appropriate conversation shifts to hip replacement, not cartilage restoration. Understanding which stage applies — and having the imaging to confirm it — is what transforms a concerning symptom into a clear, manageable plan.

1. [1] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany (2006–2022). (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
2. [2] Arthroscopic Hip Transcapsular, Translabral Delivery of Orthobiologics for Single-Stage Cartilage Repair. (2025). https://doi.org/10.1016/j.eats.2025.103587 https://doi.org/10.1016/j.eats.2025.103587
3. [3] Preserving Hip Stability Yields Better Cartilage Repair With Microfracture Treatment: A Rabbit Study. (2025). https://doi.org/10.1016/j.asmr.2025.101284 https://doi.org/10.1016/j.asmr.2025.101284
4. [4] FP3.7 Hip articular cartilage repair with autologous mesenchymal stem cells (MSCs): 4-year results in prospective controlled study. (2025). https://doi.org/10.1093/jhps/hnaf011.025 https://doi.org/10.1093/jhps/hnaf011.025